Cue Biopharma, Inc. (CUE) earnings
CUE earnings moved a median of -1.55% by the close. Quarterly and annual CUE reports and results, each read against the price at its own news timestamp. Back to the CUE overview →
21 measured CUE earnings events.
Where these CUE earnings landedvs 19 measured CUE earnings reactions
| Middle 50% of CUE earnings reactions | -10.56% to +0.04% |
|---|---|
| Median reaction (to close) | -1.55% |
| Measured reactions | 19 |
Point-in-time · zero look-ahead
Half of the 19 CUE earnings events with a measured close landed between -10.56% and +0.04%; 32% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights | Press release | +5.60% | -11.27% | |
| Form 10-Q Cue Biopharma, Inc. For: Jun 30 | SEC filing · Form 10-Q | +5.60% | -11.27% | |
| Cue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic Developments | Press release | +1.24% | -1.29% | |
| Form 10-Q Cue Biopharma, Inc. For: Mar 31 | SEC filing · Form 10-Q | +1.24% | -1.29% | |
| Form 10-K Cue Biopharma, Inc. For: Dec 31 | SEC filing · Form 10-K | -3.06% | -8.59% | |
| Cue Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights | Press release | -3.88% | — | |
| Form 10-Q Cue Biopharma, Inc. For: Sep 30 | SEC filing · Form 10-Q | -3.88% | — | |
| Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights | Press release | +0.17% | +0.04% | |
| Form 10-Q Cue Biopharma, Inc. For: Jun 30 | SEC filing · Form 10-Q | +0.17% | +0.04% | |
| Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights | Press release | -1.15% | +5.19% | |
| Form 10-Q Cue Biopharma, Inc. For: Mar 31 | SEC filing · Form 10-Q | -1.15% | +5.19% | |
| Form 10-K Cue Biopharma, Inc. For: Dec 31 | SEC filing · Form 10-K | +0.00% | -17.58% | |
| Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights | Press release | +2.67% | -17.00% | |
| Form 10-Q Cue Biopharma, Inc. For: Sep 30 | SEC filing · Form 10-Q | +2.67% | -17.00% | |
| Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights | Press release | -0.17% | +12.21% | |
| Form 10-Q Cue Biopharma, Inc. For: Jun 30 | SEC filing · Form 10-Q | +0.32% | -3.90% | |
| Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business Highlights | Press release | -0.52% | -9.85% | |
| Form 10-Q Cue Biopharma, Inc. For: Mar 31 | SEC filing · Form 10-Q | -0.52% | -9.85% | |
| Form 10-K Cue Biopharma, Inc. For: Dec 31 | SEC filing · Form 10-K | -2.59% | -1.55% | |
| Cue Biopharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights | Press release | +2.67% | +12.14% | |
| Form 10-Q Cue Biopharma, Inc. For: Sep 30 | SEC filing · Form 10-Q | +3.13% | -0.39% |
Keep exploring
More CUE: analyst actions → · SEC filings → · CUE overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Nevro Corp. (NVRO) | 253 | 0.00% | 49% |
| DarioHealth Corp. (DRIO) | 252 | 0.00% | 45% |
| DOVA PHARMACEUTICALS (DOVA) | 251 | -0.10% | 46% |
| Krystal Biotech, Inc. (KRYS) | 251 | +0.05% | 52% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.